Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 559

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 559
---
 ​ | ​ | ​                              | ​ |     — | ​ | ​ | ​ | ​    | ​ |    910 | ​ | ​ | ​ | -100%    | ​ |
| Royalty revenue            | ​ | ​ | ​                               | ​ |     — | ​ | ​ | ​ | ​    | ​ |   167 | ​ | ​ | ​ | -100%    | ​ | ​ | ​                              | ​ |     — | ​ | ​ | ​ | ​    | ​ |    415 | ​ | ​ | ​ | -100%    | ​ |
| Clinical compound revenue  | ​ | ​ | ​                               | ​ |     — | ​ | ​ | ​ | ​    | ​ |    66 | ​ | ​ | ​ | -100%    | ​ | ​ | ​                              | ​ |    84 | ​ | ​ | ​ | ​    | ​ |    165 | ​ | ​ | ​ | -49%     | ​ |
| Other revenue              | ​ | ​ | ​                               | ​ | 1,258 | ​ | ​ | ​ | ​    | ​ |     — | ​ | ​ | ​ | N/A      | ​ | ​ | ​                              | ​ | 2,872 | ​ | ​ | ​ | ​    | ​ |      — | ​ | ​ | ​ | N/A      | ​ |
| Total revenue              | ​ | ​ | ​                               | $ | 2,556 | ​ | ​ | ​ | ​    | $ | 4,866 | ​ | ​ | ​ | -47%     | ​ | ​ | ​                              | $ | 5,682 | ​ | ​ | ​ | ​    | $ | 17,964 | ​ | ​ | ​ | -68%     | ​ |

Collaborative Revenue Cara recognized collaborative revenue of $1.3 million and $2.5 million for the three months ended September 30, 2024 and 2023, respectively, and $2.1 million and $10.6 million for the nine months ended

325

TABLE OF CONTENTS

September 30, 2024 and 2023, respectively. This change in collaborative revenue for both periods was primarily related to Cara’s share of the profit from CSL Vifor’s sales of KORSUVA injection to third parties in the United States, which commercially launched in April 2022. The amount included in the